PMID

Data

Article Title

Organization

Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.

TBA

Pyrazole derivatives as partial agonists for the nicotinic acid receptor.

Leiden/Amsterdam Center For Drug Research

SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist.

Merck Research Laboratory

Discovery of a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia

TBA

Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity.

F. Hoffmann-La Roche

Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.

Merck Research Laboratories

Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.

Merck Research Laboratories

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.

Arena Pharmaceuticals

Quest for Novel Chemical Entities through Incorporation of Silicon in Drug Scaffolds.

Csir-National Chemical Laboratory